Rathbone Brothers plc maintained its position in shares of Nektar Therapeutics (NASDAQ:NKTR) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,800 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Rathbone Brothers plc’s holdings in Nektar Therapeutics were worth $348,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently bought and sold shares of NKTR. Flinton Capital Management LLC grew its position in shares of Nektar Therapeutics by 11.1% during the 1st quarter. Flinton Capital Management LLC now owns 4,480 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 448 shares during the period. Louisiana State Employees Retirement System grew its position in shares of Nektar Therapeutics by 0.8% during the 2nd quarter. Louisiana State Employees Retirement System now owns 63,200 shares of the biopharmaceutical company’s stock worth $1,236,000 after buying an additional 500 shares during the period. LS Investment Advisors LLC grew its position in shares of Nektar Therapeutics by 8.8% during the 2nd quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 535 shares during the period. World Asset Management Inc grew its holdings in Nektar Therapeutics by 5.6% during the second quarter. World Asset Management Inc now owns 10,167 shares of the biopharmaceutical company’s stock valued at $199,000 after purchasing an additional 539 shares during the period. Finally, Municipal Employees Retirement System of Michigan grew its holdings in Nektar Therapeutics by 1.7% during the first quarter. Municipal Employees Retirement System of Michigan now owns 34,920 shares of the biopharmaceutical company’s stock valued at $820,000 after purchasing an additional 570 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by BBNS and is the property of of BBNS. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://baseballnewssource.com/markets/rathbone-brothers-plc-maintains-stake-in-nektar-therapeutics-nktr/1612470.html.
In other news, CEO Howard W. Robin sold 91,714 shares of the stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $19.26, for a total value of $1,766,411.64. Following the sale, the chief executive officer now directly owns 152,504 shares of the company’s stock, valued at $2,937,227.04. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Jillian B. Thomsen sold 2,648 shares of the stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $19.32, for a total value of $51,159.36. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 320,962 shares of company stock worth $6,615,210. 6.10% of the stock is owned by insiders.
A number of research analysts recently issued reports on the stock. Jefferies Group LLC restated a “buy” rating and set a $23.00 price objective on shares of Nektar Therapeutics in a report on Friday, July 21st. Zacks Investment Research raised shares of Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a research note on Tuesday, August 1st. William Blair reissued an “outperform” rating on shares of Nektar Therapeutics in a research report on Tuesday, July 18th. ValuEngine raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, HC Wainwright assumed coverage on shares of Nektar Therapeutics in a report on Monday, August 7th. They issued a “buy” rating and a $31.00 price objective on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company. Nektar Therapeutics has a consensus rating of “Buy” and a consensus price target of $26.10.
Nektar Therapeutics (NASDAQ NKTR) opened at 22.43 on Friday. The company’s market capitalization is $3.51 billion. The company has a 50 day moving average price of $20.15 and a 200-day moving average price of $19.77. Nektar Therapeutics has a one year low of $11.41 and a one year high of $24.88.
Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.04). The firm had revenue of $34.60 million during the quarter, compared to analysts’ expectations of $33.64 million. Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. Nektar Therapeutics’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.36) earnings per share. Analysts expect that Nektar Therapeutics will post ($0.94) EPS for the current fiscal year.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with our FREE daily email newsletter.